Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid Alzheimer's drug that works
It’s been decades and dozens of drugs, and most of them failed, but the amyloid hypothesis won’t go gently into the night.
While the world awaits the FDA’s decision on Biogen’s controversial aducanumab pitch, a Big Pharma rival says they now have data to support their own amyloid-clearing Alzheimer’s drug.
Eli Lilly said Monday that their beta amyloid-targeting antibody donanemab had reduced the rate of decline in moderate Alzheimer’s patients in a randomized Phase II trial. Patients who received the drug declined 32% more slowly than those on placebo, as measured by standard diagnostic scales for the condition, Lilly said. The company said the results were statistically significant but didn’t disclose a p-value.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.